Myasthenia gravis does not affect life expectancy if the disease is well controlled and does not involve the respiratory and pharyngeal muscles.
Myasthenia gravis is an autoimmune disease, mainly due to the neuromuscular junction in the conduction process caused by the obstacle, there is no special, curable treatment, only through symptomatic treatment to improve the condition.
If myasthenia gravis has no complications, the condition is stable, and timely symptomatic treatment is given, the condition can be effectively controlled, and generally will not affect life expectancy.
Severe myasthenia gravis, such as medullary muscle type and generalized myasthenia gravis, is prone to respiratory distress and life-threatening; the development of the disease, the improper application of drugs, infections, childbirth, surgery, and many other factors can lead to myasthenia gravis crisis, resulting in respiratory muscle weakness, and may die at any time if treatment is not carried out in a timely manner.
Patients with myasthenia gravis, it is recommended to standardize drug therapy under the guidance of physicians, should avoid the use of myasthenia gravis-inducing drugs.